Imetelstat Is Effective Treatment for Patients With Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 01期
关键词：
GRN163;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [1] Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels
    Mascarenhas, John
    Komrokji, Rami S.
    Cavo, Michele
    Martino, Bruno
    Niederwieser, Dietger
    Reiter, Andreas
    Scott, Bart L.
    Baer, Maria R.
    Hoffman, Ronald
    Odenike, Olatoyosi
    Bussolari, Jacqueline
    Zhu, Eugene
    Huang, Fei
    Rose, Esther
    Sherman, Laurie
    Dougherty, Souria
    Feller, Faye M.
    Kiladjian, Jean-Jacques
    [J]. BLOOD, 2018, 132
  • [2] MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
    Mascarenhas, John
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Komrokji, Rami S.
    Koschmieder, Steffen
    Vannucchi, Alessandro M.
    Berry, Tymara
    Redding, Denise
    Sherman, Laurie
    Dougherty, Souria
    Peng, Lixian
    Sun, Libo
    Huang, Fei
    Wan, Ying
    Feller, Faye
    Verstovsek, Srdan
    [J]. BLOOD, 2022, 140 : 6826 - 6829
  • [3] The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase OAK) inhibitor: A phase 2, randomized study.
    Tefferi, Ayalew
    Gangat, Naseema
    Niederwieser, Dietger
    Van Droogenbroeck, Jan
    Baer, Maria R.
    Kiladjian, Jean-Jacques
    Hoffman, Ronald
    Finazzi, Guido
    Cervantes, Francisco
    Gotlib, Jason R.
    Sirhan, Shireen
    Apperley, Jane
    Langlois, Angelique
    Wan, Ying
    Sherman, Laurie Jill
    Dougherty, Souria
    Feller, Faye
    Odenike, Olatoyosi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design
    Mascarenhas, John
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    Komrokji, Rami S.
    Koschmieder, Steffen
    Vannucchi, Alessandro M.
    Berry, Tymara
    Redding, Denise
    Sherman, Laurie
    Dougherty, Souria
    Peng, Lixian
    Sun, Libo
    Huang, Fei
    Wan, Ying
    Feller, Faye M.
    Rizo, Aleksandra
    Verstovsek, Srdan
    [J]. FUTURE ONCOLOGY, 2022, 18 (22) : 2393 - 2402
  • [5] A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
    Mascarenhas, John
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Mesa, Ruben
    Komrokji, Rami S.
    Koschmieder, Steffen
    Vannucchi, Alessandro M.
    Berry, Tymara
    Sherman, Laurie
    Dougherty, Souria
    Sun, Libo
    Huang, Fei
    Wan, Ying
    Feller, Faye
    Rizo, Aleksandra
    Verstovsek, Srdan
    [J]. BLOOD, 2020, 136
  • [6] A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
    Mascarenhas, John
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    Komrokji, Rami S.
    Koschmieder, Steffen
    Vannucchi, Alessandro
    Berry, Tymara
    Sherman, Laurie
    Dougherty, Souria
    Sun, Libo
    Huang, Fei
    Wan, Ying
    Feller, Faye
    Rizo, Aleksandra
    Verstovsek, Srdan
    [J]. BLOOD, 2021, 138
  • [7] UPDATED RESULTS FROM A RANDOMIZED PHASE 2 DOSE-RANGING STUDY OF THE JAK2-SELECTIVE INHIBITOR SAR302503 IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF)
    Talpaz, M.
    Jamieson, C.
    Gabrail, N.
    Lebedinsky, C.
    Gao, G.
    Patki, A.
    Lui, F.
    Tefferi, A.
    Pardanani, A.
    [J]. HAEMATOLOGICA, 2013, 98 : 458 - 458
  • [8] Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial
    Pardanani, Animesh
    Tefferi, Ayalew
    Masszi, Tamas
    Mishchenko, Elena
    Drummond, Mark W.
    Jourdan, Eric
    Vannucchi, Alessandro M.
    Jurgutis, Mindaugas
    Ribrag, Vincent
    Rambaldi, Alessandro
    Koh, Liang Piu
    Rose, Shelonitda
    Zhang, Jun
    Harrison, Claire
    [J]. BLOOD, 2020, 136
  • [9] Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis
    Zhang, Yi
    Zhou, Hu
    Jiang, Zhongxing
    Wu, DengShu
    Zhuang, Junling
    Li, Wei
    Jiang, Qian
    Wang, XiuLi
    Huang, Jinwen
    Zhu, Huan-Ling
    Zhang, RuiJuan
    Du, Xin
    Fei, Li
    Xiang, Ruixiang
    Zhang, Feng
    Hu, Jianda
    Li, Yan
    Hu, Yu
    Liu, Jing
    Jin, ChengHao
    Sun, Kai
    Zhou, Ze-Ping
    Jin, Jie
    [J]. BLOOD, 2021, 138
  • [10] A Phase I Study of TP-3654, an Oral PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis (MF)
    Lebedinsky, Claudia
    Kabir, Sujan
    Warner, Steven
    Mohi, Golam
    Yang, Huyuan
    Mei, Jian
    Braendle, Edgar
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S355 - S356
12345